Literature DB >> 19760954

High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma.

Takao Tamesa1, Norio Iizuka, Naohide Mori, Toshimasa Okada, Norikazu Takemoto, Akira Tangoku, Masaaki Oka.   

Abstract

BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) reportedly affects the metastatic potential of tumors. We investigated in patients whether association exits between perioperative serum VEGF levels and recurrence of hepatocellular carcinoma (HCC).
METHODOLOGY: Thirty-two patients who underwent curative resection for HCC were enrolled in this study. Blood samples were obtained at 6 points during the perioperative period: preoperative day and, postoperative days 1, 2, 3, 7 and 14). Serum VEGF levels were measured by enzyme-linked immunosorbent assay. We divided the 32 hepatocellular carcinoma patients into a high VEGF group (preoperative serum level > or = 100 pg/ ml, n = 10) and a low VEGF group (preoperative serum level < 100 pg/ml, n = 22).
RESULTS: During a median follow-up period of 27.1 months, the cancer recurred in 20 of the 32 patients. Disease-free survival in the high VEGF group was significantly poorer than that in the low VEGF group (p < 0.05). Serum VEGF levels in the high VEGF group remained significantly higher than those in the low VEGF group after hepatectomy (p < 0.05). Serum VEGF levels in the recurrent group were also significantly higher than those in the non recurrent group at preoperative day, postoperative days 2, 3 and 7 (p < 0.05).
CONCLUSIONS: High serum VEGF levels during perioperative period may be a risk factor for intrahepatic recurrence after complete resection for HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760954

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  9 in total

1.  TIE2-expressing monocytes: a possible cellular diagnostic and prognostic biomarker for hepatocellular carcinoma.

Authors:  Luigi Buonaguro
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 2.  Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

Authors:  Catherine Frenette; Robert Gish
Journal:  World J Gastroenterol       Date:  2012-02-14       Impact factor: 5.742

Review 3.  HCC and angiogenesis: possible targets and future directions.

Authors:  Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2011-03-08       Impact factor: 66.675

Review 4.  Hepatocellular carcinoma: Where there is unmet need.

Authors:  Manojkumar Bupathi; Ahmed Kaseb; Funda Meric-Bernstam; Aung Naing
Journal:  Mol Oncol       Date:  2015-06-25       Impact factor: 6.603

5.  Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Qian Qian; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-08       Impact factor: 7.293

6.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

7.  Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma.

Authors:  Matthias Pinter; Wolfgang Sieghart; Monika Schmid; Bernhard Dauser; Gerald Prager; Hans Peter Dienes; Michael Trauner; Markus Peck-Radosavljevic
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

8.  Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.

Authors:  Kaoru Tsuchiya; Yasuhiro Asahina; Shuya Matsuda; Masaru Muraoka; Toru Nakata; Yuichiro Suzuki; Nobuharu Tamaki; Yutaka Yasui; Shoko Suzuki; Takanori Hosokawa; Takashi Nishimura; Ken Ueda; Teiji Kuzuya; Hiroyuki Nakanishi; Jun Itakura; Yuka Takahashi; Masayuki Kurosaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Cancer       Date:  2013-10-07       Impact factor: 6.860

9.  Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma.

Authors:  Kazuaki Ozaki; Nobuyuki Toshikuni; Joseph George; Takahiro Minato; Yasuhiro Matsue; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  J Cancer       Date:  2014-03-04       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.